ACTION II

A Clinical Trial In Overt Nephropathy II. A trial that asked whether pharmacologic inhibition of advanced glycated endproduct (AGE) production with pimagedine slowed the progression of chronic renal disease in type 2 diabetics.
Conclusion No. Safety concerns and lack of efficacy resulted in the drug’s sponsor ending the trial.

Mentioned in

action

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.